![]() | |
Names | |
---|---|
IUPAC name
2-Deoxy-2-[18F]fluoroglucose
| |
Identifiers | |
| |
3D model (JSmol)
|
|
Abbreviations | [18F]FDG |
2047723 | |
ChEBI | |
ChEMBL | |
ChemSpider | |
KEGG | |
PubChem CID
|
|
UNII | |
CompTox Dashboard (EPA)
|
|
| |
| |
Properties | |
C6H1118FO5 | |
Molar mass | 181.1495 g mol−1 |
Melting point | 170 to 176[1] °C (338 to 349 °F; 443 to 449 K) |
Pharmacology | |
V09IX04 (WHO) | |
| |
Intravenous | |
Pharmacokinetics: | |
6-Phosphorylation | |
110 min (at 70%) 16 min (at 20%) | |
20% Radioactivity renally excreted in two hours | |
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
|
[18F]Fluorodeoxyglucose (INN), or fluorodeoxyglucose F 18 (USAN and USP), also commonly called fluorodeoxyglucose and abbreviated [18F]FDG, 2-[18F]FDG or FDG, is a radiopharmaceutical, specifically a radiotracer, used in the medical imaging modality positron emission tomography (PET). Chemically, it is 2-deoxy-2-[18F]fluoro-D-glucose, a glucose analog, with the positron-emitting radionuclide fluorine-18 substituted for the normal hydroxyl group at the C-2 position in the glucose molecule.
The uptake of [18F]FDG by tissues is a marker for the tissue uptake of glucose, which in turn is closely correlated with certain types of tissue metabolism. After [18F]FDG is injected into a patient, a PET scanner can form two-dimensional or three-dimensional images of the distribution of [18F]FDG within the body.
Since its development in 1976, [18F]FDG had a profound influence on research in the neurosciences.[2] The subsequent discovery in 1980 that [18F]FDG accumulates in tumors underpins the evolution of PET as a major clinical tool in cancer diagnosis.[3] [18F]FDG is now the standard radiotracer used for PET neuroimaging and cancer patient management.[4]
The images can be assessed by a nuclear medicine physician or radiologist to provide diagnoses of various medical conditions.